LON:HSM

Samuel Heath & Sons Competitors

GBX 355
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
379.50
Now: GBX 355
379.50
50-Day Range
345
MA: GBX 351.20
355
52-Week Range
178
Now: GBX 355
390
Volume102 shs
Average Volume1,647 shs
Market Capitalization£9.00 million
P/E Ratio15.17
Dividend Yield5.76%
BetaN/A

Competitors

Samuel Heath & Sons (LON:HSM) Vs. CRH, BREE, IBST, FAN, TYMN, and FORT

Should you be buying HSM stock or one of its competitors? Companies in the industry of "building materials" are considered alternatives and competitors to Samuel Heath & Sons, including CRH (CRH), Breedon Group (BREE), Ibstock (IBST), Volution Group (FAN), Tyman (TYMN), and Forterra (FORT).

Samuel Heath & Sons (LON:HSM) and CRH (LON:CRH) are both basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Dividends

Samuel Heath & Sons pays an annual dividend of GBX 0.06 per share and has a dividend yield of 0.0%. CRH pays an annual dividend of GBX 84 per share and has a dividend yield of 2.4%. Samuel Heath & Sons pays out 0.2% of its earnings in the form of a dividend. CRH pays out 81.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Valuation and Earnings

This table compares Samuel Heath & Sons and CRH's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Samuel Heath & Sons£11.82 million0.76N/AGBX 23.4015.17
CRH£27.59 billion0.99N/AGBX 103.1033.80

Samuel Heath & Sons is trading at a lower price-to-earnings ratio than CRH, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Samuel Heath & Sons and CRH's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Samuel Heath & SonsN/AN/AN/A
CRHN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Samuel Heath & Sons and CRH, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Samuel Heath & Sons0000N/A
CRH01102.50

CRH has a consensus price target of GBX 3,600, suggesting a potential upside of 3.30%. Given CRH's higher possible upside, analysts plainly believe CRH is more favorable than Samuel Heath & Sons.

Summary

CRH beats Samuel Heath & Sons on 7 of the 8 factors compared between the two stocks.

Breedon Group (LON:BREE) and Samuel Heath & Sons (LON:HSM) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Breedon Group and Samuel Heath & Sons' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Breedon GroupN/AN/AN/A
Samuel Heath & SonsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Breedon Group and Samuel Heath & Sons, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Breedon Group01302.75
Samuel Heath & Sons0000N/A

Breedon Group currently has a consensus target price of GBX 95.50, suggesting a potential upside of 1.60%. Given Breedon Group's higher possible upside, analysts plainly believe Breedon Group is more favorable than Samuel Heath & Sons.

Earnings and Valuation

This table compares Breedon Group and Samuel Heath & Sons' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Breedon Group£928.70 million1.71N/AGBX 247.00
Samuel Heath & Sons£11.82 million0.76N/AGBX 23.4015.17

Samuel Heath & Sons is trading at a lower price-to-earnings ratio than Breedon Group, indicating that it is currently the more affordable of the two stocks.

Summary

Breedon Group beats Samuel Heath & Sons on 5 of the 6 factors compared between the two stocks.

Ibstock (LON:IBST) and Samuel Heath & Sons (LON:HSM) are both small-cap basic materials companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Ibstock and Samuel Heath & Sons, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ibstock03402.57
Samuel Heath & Sons0000N/A

Ibstock presently has a consensus price target of GBX 206.50, indicating a potential downside of 10.22%. Given Ibstock's higher probable upside, research analysts plainly believe Ibstock is more favorable than Samuel Heath & Sons.

Valuation & Earnings

This table compares Ibstock and Samuel Heath & Sons' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ibstock£316.17 million2.98N/AGBX (6.80)-33.82
Samuel Heath & Sons£11.82 million0.76N/AGBX 23.4015.17

Ibstock is trading at a lower price-to-earnings ratio than Samuel Heath & Sons, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ibstock and Samuel Heath & Sons' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IbstockN/AN/AN/A
Samuel Heath & SonsN/AN/AN/A

Summary

Ibstock beats Samuel Heath & Sons on 4 of the 6 factors compared between the two stocks.

Volution Group (LON:FAN) and Samuel Heath & Sons (LON:HSM) are both small-cap basic materials companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Profitability

This table compares Volution Group and Samuel Heath & Sons' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Volution GroupN/AN/AN/A
Samuel Heath & SonsN/AN/AN/A

Valuation & Earnings

This table compares Volution Group and Samuel Heath & Sons' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Volution Group£229.60 million3.58N/AGBX 5.3078.49
Samuel Heath & Sons£11.82 million0.76N/AGBX 23.4015.17

Samuel Heath & Sons is trading at a lower price-to-earnings ratio than Volution Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Volution Group and Samuel Heath & Sons, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Volution Group00303.00
Samuel Heath & Sons0000N/A

Volution Group presently has a consensus price target of GBX 410, indicating a potential downside of 1.44%. Given Volution Group's higher probable upside, research analysts plainly believe Volution Group is more favorable than Samuel Heath & Sons.

Summary

Volution Group beats Samuel Heath & Sons on 5 of the 6 factors compared between the two stocks.

Samuel Heath & Sons (LON:HSM) and Tyman (LON:TYMN) are both small-cap basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Samuel Heath & Sons and Tyman, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Samuel Heath & Sons0000N/A
Tyman01202.67

Tyman has a consensus target price of GBX 315, indicating a potential downside of 21.54%. Given Tyman's higher possible upside, analysts clearly believe Tyman is more favorable than Samuel Heath & Sons.

Profitability

This table compares Samuel Heath & Sons and Tyman's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Samuel Heath & SonsN/AN/AN/A
TymanN/AN/AN/A

Valuation & Earnings

This table compares Samuel Heath & Sons and Tyman's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Samuel Heath & Sons£11.82 million0.76N/AGBX 23.4015.17
Tyman£572.80 million1.38N/AGBX 1921.13

Samuel Heath & Sons is trading at a lower price-to-earnings ratio than Tyman, indicating that it is currently the more affordable of the two stocks.

Summary

Tyman beats Samuel Heath & Sons on 5 of the 6 factors compared between the two stocks.

Forterra (LON:FORT) and Samuel Heath & Sons (LON:HSM) are both small-cap basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Earnings and Valuation

This table compares Forterra and Samuel Heath & Sons' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forterra£291.90 million2.31N/AGBX (2.60)-113.46
Samuel Heath & Sons£11.82 million0.76N/AGBX 23.4015.17

Forterra is trading at a lower price-to-earnings ratio than Samuel Heath & Sons, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Forterra and Samuel Heath & Sons, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forterra04302.43
Samuel Heath & Sons0000N/A

Forterra currently has a consensus target price of GBX 219.67, suggesting a potential downside of 25.54%. Given Forterra's higher possible upside, equities analysts plainly believe Forterra is more favorable than Samuel Heath & Sons.

Profitability

This table compares Forterra and Samuel Heath & Sons' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForterraN/AN/AN/A
Samuel Heath & SonsN/AN/AN/A

Summary

Forterra beats Samuel Heath & Sons on 4 of the 6 factors compared between the two stocks.


Samuel Heath & Sons Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CRH logo
CRH
CRH
0.9$3,485.00flat£27.39 billion£27.59 billion33.80
Breedon Group logo
BREE
Breedon Group
1.0$94.00flat£1.59 billion£928.70 million47.00News Coverage
Ibstock logo
IBST
Ibstock
0.9$230.00flat£941.99 million£316.17 million-33.82
Volution Group logo
FAN
Volution Group
0.9$416.00flat£822.03 million£229.60 million78.49
Tyman logo
TYMN
Tyman
1.2$401.50flat£788.14 million£572.80 million21.13News Coverage
Forterra logo
FORT
Forterra
0.8$295.00flat£674.51 million£291.90 million-113.46Gap Down
SRC
SigmaRoc
0.9$85.50flat£238.32 million£95.09 million61.07High Trading Volume
Michelmersh Brick logo
MBH
Michelmersh Brick
1.0$157.50flat£147.96 million£52.04 million32.14
The Alumasc Group logo
ALU
The Alumasc Group
1.6$203.00flat£73.35 million£80.44 million15.04Insider Buying
Gap Down
TON
Titon
1.1$122.50flat£13.65 million£20.65 million245.00Gap Up
Genuit Group logo
PLP
Genuit Group
1.5$1.06flat£2.62 million£398.60 million0.13
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.